Here are the best candidates in an “unprecedented” race for a coronavirus vaccine

0
79


Gradual relaxation of coronavirus restrictions is raising hopes for an economic rebound as the biotech industry rides a wave of expectations in the search for an effective treatment for COVID-19. “Data-reactid =” 16 “> The gradual relaxation of restrictions on coronaviruses is fueling hope for an economic rebound, the biotechnology industry riding a wave of expectations in the search for a COVID treatment- 19 effective.

as a key to ending the work and life constraints that have decimated the global economy, which return to a sense of normalcy. Worldwide, there are nearly 5 million positive cases and more than 300,000 have been killed by the virus. “Data-reactid =” 17 “> Vaccines are seen as the key to ending the work and life constraints that have decimated the global economy and to come back Worldwide, there are almost 5 million positive cases and more than 300,000 have been killed by the virus.

Nations are locked in an intense effort to demonstrate their biotechnological capabilities in the global fight against COVID-19. “Data-reactid =” 18 “> With so many challenges, the global pipeline has become an intense space race for the new era. Nations are locked in an intense effort to demonstrate their biotechnological capabilities in the global fight against COVID-19.

In collaboration with branches of the U.S. Health and Human Services (HHS) and the National Institute of Health (NIH), large and small pharmaceutical companies are working on vaccines.

MRNA) and Pfizer (PFE), both of which use messenger RNA technology – a newer technology that does not exist in the current drug market. The two have entered human clinical trials. Abroad, all eyes are on the Chinese CanSino, and a project in progress at the University of Oxford in the United Kingdom “data-reactid =” 20 “> For the moment, the most distant are Moderna (MRNA) and Pfizer (PFE), both of which use messenger RNA technology – a newer technology that does not exist in the current drug market. Both have entered human clinical trials.

Currently, “there are at least a hundred horses in the race, and we have some leaders at the front,” Marc Poznansky, director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, told Yahoo Finance recently.

He added that it was “unprecedented to have so many platforms in play to test a product in an attempt to go first in human trials.”

This photo taken on May 23, 2020 shows a laboratory technician holding a dose of a new COVID-19 coronavirus vaccine candidate ready to be tested on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. – After conclusive results in mice, Thai scientists from the center began testing a new COVID-19 coronavirus vaccine candidate in monkeys, the phase before the human trials. (Photo by Mladen ANTONOV / AFP) (Photo by MLADEN ANTONOV / AFP via Getty Images)

less than a dozen of which have entered clinical trials. Some are developed in coordination with governments, while others are the result of industrial or university collaboration. “Data-reactid =” 43 “> The World Health Organization is increasingly monitoring the field, where fewer than a dozen have participated in clinical trials. Some are developed in coordination with governments, while others are the result of industrial or university collaboration.

“Ambitious” at best. “Data-reactid =” 44 “> Expectations have placed unprecedented demand on a” pandemic market “that could potentially be valued at between $ 10 billion and $ 30 billion, analysts at Morgan Stanley. But effective treatment is unlikely before the first half of 2021 at the earliest, with many health experts warning that aggressive development times are at best “ambitious”.

try to determine the winners and losers of this high stakes race. “Data-reactid =” 45 “> However, pharmaceutical companies are reorienting existing drugs and trying to find treatments for people currently infected with the virus, with investors trying to determine the winners and losers in this high-stakes race. .

There are more than 1.5 million cases of coronavirus in the United States (Graphic: David Foster / Yahoo Finance)

expand its reach globally, as the United States struggles to strike a balance between urgency and security and meet the needs of the country first. “Data-reactid =” 67 “> The two largest economies in the world are engaged in fierce competition for a vaccine. China to strengthen biotech industry and expand reach globally, while U.S. fights to strike a balance between emergency and safety and meet needs first .

In order to overcome the widening scope of vaccine candidates, the United States deployed Operation Warp Speed, using $ 3 billion in Congress funding to fund vaccine development. Meanwhile, the U.S. Food and Drug Administration is working closely with pharmaceutical companies to follow accelerated timelines for clinical trials, as pharmaceutical companies aim to produce billions of doses as soon as a candidate is viable.

Global collaborations through WHO and a concerted effort within the European Union are also at stake. WHO officials also recently said that they work with the public and private sector in India, which has a massive vaccine production capacity, to produce the vaccines for the world.

Private institutions such as the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness (CEPI) are also looking for candidates.

In the U.S., Moderna has received $ 483 million in funding from HARD’s Biomedical Advanced Research and Development Authority (BARDA) and is developing its treatment in collaboration with the National Institute of Allergy and Infectious Diseases, the agency headed by Dr Anthony Fauci.

leveraged the capital market to produce one billion doses of vaccine annually, which it does in partnership with Swiss manufacturer Lonza Group. “Data-reactid =” 76 “> Recently, Moderna exploited the capital market with the aim of producing one billion doses of vaccine per year, which it does in partnership with the Swiss manufacturer Lonza Group.

to develop their own vaccine, by pivoting their work together on a flu treatment. “Data-reactid =” 77 “> In addition, Pfizer has established a partnership with German biotechnology BioNTech to develop its own vaccine, based on their work together on a treatment against influenza.

SNY) and GlaxoSmithKline (GSK) are engaged in a joint effort in the race; meanwhile, Johnson & amp; Johnson (JNJ) are among the biggest pharmaceutical competitors and have also obtained support from BARDA. “Data-reactid =” 78 “> Sanofi (SNY) and GlaxoSmithKline (GSK) are engaged in a joint effort in the race; Meanwhile, Johnson & Johnson (JNJ) are among the biggest pharmaceutical competitors and have also obtained support from BARDA.

INO) and Novavax (NVAX), have received funding from CEPI and are also working on vaccines. Inovio, which had previously worked on another coronavirus vaccine, was the second company in the United States to begin clinical trials with its candidate. While data from clinical trials are pending, preclinical data have shown positive results in animal studies. “Data-reactid =” 79 “> Two small biotechnologies, Inovio (INO) and Novavax (NVAX), have received funding from CEPI and are also working on vaccines. Inovio, who had previously worked on another coronavirus vaccine, was the second company in the United States to begin clinical trials with its candidate. Although data from clinical trials are pending, preclinical data have shown positive results in animal studies.

China and the world

with the support of the government, which is aggressively trying to prove itself in the world. This includes a commitment to support WHO and plans to share its vaccine with the world. “Data-reactid =” 81 “> China has a young biotechnology industry, which has been growing rapidly in recent years with the support of the government, which is actively trying to prove itself in the world. This includes his commitment to support WHO and his intention to share his vaccines with the world.

former executive of Sanofi to manage its international commercial operations. “Data-reactid =” 82 “> CanSino Biologics, with its partner Beijing Institute of Biotechnology, is leading the world with a vaccine to be approved by fall 2020 in China. The company recently hired a former Sanofi executive to manage its international business operations.

Two other main competitors are Sinopharm – which is working on clinical trials with the Wuhan Biologicals Institute and the Beijing Biologicals Institute – and another from Sinovac.

Meanwhile, the UK has also invested in a candidate vaccine from the University of Oxford, which also plans to provide its treatment globally. The university is partnering with pharmaceutical giant AstraZeneca and the Serum Institute in India to distribute its potential vaccine.

invest in a new production plant to ensure mass production by next summer. “Data-reactid =” 85 “> The British government is also investing in a new production plant for mass production by next summer.

LEAVE A REPLY

Please enter your comment!
Please enter your name here